Moleculin Biotech, Inc.
Groundbreaking Cancer Therapies
22 employees · est. 2006 · Houston, United States
Moleculin Biotech, Inc. is the older company (2011 vs 2006).
Side-by-Side Comparison
| Metric | Kangpu Biopharmaceuticals, Ltd. | Moleculin Biotech, Inc. |
|---|---|---|
| Founded | ||
| Founded | 2011 | 2006 older |
| Headquarters | ||
| Headquarters | China | Houston, United States |
| Employees | ||
| Employees | 14 | 22 |
| Industry | ||
| Industry | Biopharma, Health Care, Pharmaceutical | Biotechnology, Pharmaceutical |
| Funding Stage | ||
| Funding Stage | Series B | Post Ipo Equity |
| Total Funding | ||
| Total Funding | $364.00M | Not tracked yet |
| Funding Rounds | ||
| Funding Rounds | 3 | 8 |
| Services | ||
| Services | Not tracked yet | Not tracked yet |
| Target Customers | ||
| Target Customers | Not tracked yet | Not tracked yet |
| Taxonomy | ||
| Taxonomy | Biopharmaceuticals, Clinical-stage Company, Drug Discovery, Small Molecules, Cancer Treatment, Autoimmune Diseases, Inflammatory Disorders, Targeted Protein Ubiquitination, Ubiquitin-protein Degradation, X-Synergy®, Metastatic Castration-resistant Prostate Cancer, Immuno-modulating Drugs, Drug Development, Precision Medicine | Oncology Drug Development, Clinical-stage Pharmaceuticals, Multidrug Resistance Mechanisms, Anthracycline Drug Development, Immunostimulating Drug Development, Treatment Of Soft Tissue Sarcoma, Treatment Of Acute Myeloid Leukemia, Antimetabolite Drug Development, COVID-19 Antiviral Drug Development, Brain Tumor Treatment, Pancreatic Cancer Treatment, Cutaneous T-cell Lymphoma Treatment, Drug Development From M.D. Anderson Cancer Center Discoveries, STAT3 Inhibitors, Tumor Metabolism Targeting |
| Website | ||
| Website | kangpugroup.com | moleculin.com |
About Kangpu Biopharmaceuticals, Ltd.
Kangpu Biopharmaceuticals, Ltd. is a China-based biopharmaceutical startup founded in 2011. The company focuses on developing innovative small molecules for treating solid tumors, hematological malignancies, auto-immune diseases, and inflammatory disorders. It specializes in targeted protein ubiquit...
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. (NASDAQ: MBRX) is a clinical stage pharmaceutical company with a focus on developing a diverse portfolio of drug candidates aimed at treating highly resistant tumors and viruses. The company's lead program, Annamycin, is an innovative anthracycline designed to circumvent mult...
We will tell you when either one moves
BounceWatch watches Kangpu Biopharmaceuticals, Ltd. and Moleculin Biotech, Inc. for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Kangpu Biopharmaceutic... and Moleculin Biotech, Inc... — by email.
Frequently Asked Questions
Compare Kangpu Biopharmaceuticals, Ltd. with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at Kangpu Biopharmaceuticals, Ltd. on 12 Sep 2024, and Moleculin Biotech, Inc. on 20 Dec 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.